FDG PET scans as evaluation of clinical response to dendritic cell vaccination in patients with malignant melanoma.

about

Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response.

P2860

Q36277032-0C21BE82-9F54-409B-ACF9-FB9DCC28A550 Q38912265-1F4B9705-8220-43E6-BAEB-6610CF38B27F

P2860

FDG PET scans as evaluation of clinical response to dendritic cell vaccination in patients with malignant melanoma.

Item

http://www.wikidata.org/entity/Q46165601

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

FDG PET scans as evaluation of ...... ients with malignant melanoma.

@en

FDG PET scans as evaluation of ...... ients with malignant melanoma.

@nl

type

Item

label

FDG PET scans as evaluation of ...... ients with malignant melanoma.

@en

FDG PET scans as evaluation of ...... ients with malignant melanoma.

@nl

prefLabel

FDG PET scans as evaluation of ...... ients with malignant melanoma.

@en

FDG PET scans as evaluation of ...... ients with malignant melanoma.

@nl

P1476

FDG PET scans as evaluation of ...... ients with malignant melanoma.

@en

P2093

Helle H Johannesen

http://www.w3.org/2001/XMLSchema#string

Helle W Hendel

http://www.w3.org/2001/XMLSchema#string

Lotte Engell-Noerregaard

http://www.w3.org/2001/XMLSchema#string

Louise Alslev

http://www.w3.org/2001/XMLSchema#string

P2860

Improved endpoints for cancer immunotherapy trials

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma.

Validation of novel imaging methodologies for use as cancer clinical trial end-points

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Chemoimmunotherapy.

P2888

s00262-012-1306-5

P304

17-25

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-012-1306-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Inge Marie Svane

P577

2012-06-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22722450

http://www.w3.org/2001/XMLSchema#string

FDG PET scans as evaluation of clinical response to dendritic cell vaccination in patients with malignant melanoma.

about

P2860

P2860

FDG PET scans as evaluation of clinical response to dendritic cell vaccination in patients with malignant melanoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698